Shine Technologies and Taiwan-based Primo Biotechnology have signed a supply and distribution agreement that will allow Primo to introduce lutetium-177 (Lu-177) to a broader Asia-Pacific market.
Under the agreement, Primo secures exclusive distribution rights for Shine’s Lu-177 medical isotope (Ilumira) in Taiwan, along with sales rights in Japan, South Korea, and Singapore. Primo will also have priority access to Shine’s other therapeutic isotopes, ensuring a reliable supply for emerging nuclear medicine therapies, the companies said.
Lu-177 is a medical isotope in high demand for use in radioligand therapy to treat cancer.